Literature DB >> 14740320

Mutations within the MGC4607 gene cause cerebral cavernous malformations.

C Denier1, S Goutagny, P Labauge, V Krivosic, M Arnoult, A Cousin, A L Benabid, J Comoy, P Frerebeau, B Gilbert, J P Houtteville, M Jan, F Lapierre, H Loiseau, P Menei, P Mercier, J J Moreau, A Nivelon-Chevallier, F Parker, A M Redondo, J M Scarabin, M Tremoulet, M Zerah, J Maciazek, E Tournier-Lasserve.   

Abstract

Cerebral cavernous malformations (CCM) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. They cause seizures and focal neurological deficits due to cerebral hemorrhages. CCM loci have already been assigned to chromosomes 7q (CCM1), 7p (CCM2), and 3q (CCM3) and have been identified in 40%, 20%, and 40%, respectively, of families with CCM. Loss-of-function mutations have been identified in CCM1/KRIT1, the sole CCM gene identified to date. We report here the identification of MGC4607 as the CCM2 gene. We first reduced the size of the CCM2 interval from 22 cM to 7.5 cM by genetic linkage analysis. We then hypothesized that large deletions might be involved in the disorder, as already reported in other hamartomatous conditions, such as tuberous sclerosis or neurofibromatosis. We performed a high-density microsatellite genotyping of this 7.5-cM interval to search for putative null alleles in 30 unrelated families, and we identified, in 2 unrelated families, null alleles that were the result of deletions within a 350-kb interval flanked by markers D7S478 and D7S621. Additional microsatellite and single-nucleotide polymorphism genotyping showed that these two distinct deletions overlapped and that both of the two deleted the first exon of MGC4607, a known gene of unknown function. In both families, one of the two MGC4607 transcripts was not detected. We then identified eight additional point mutations within MGC4607 in eight of the remaining families. One of them led to the alteration of the initiation codon and five of them to a premature termination codon, including one nonsense, one frameshift, and three splice-site mutations. All these mutations cosegregated with the disease in the families and were not observed in 192 control chromosomes. MGC4607 is so far unrelated to any known gene family. Its implication in CCMs strongly suggests that it is a new player in vascular morphogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14740320      PMCID: PMC1181930          DOI: 10.1086/381718

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Interaction between krit1 and icap1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation.

Authors:  J Zhang; R E Clatterbuck; D Rigamonti; D D Chang; H C Dietz
Journal:  Hum Mol Genet       Date:  2001-12-01       Impact factor: 6.150

2.  Germline mutations in the CCM1 gene, encoding Krit1, cause cerebral cavernous malformations.

Authors:  M Lucas; A F Costa; M Montori; F Solano; M D Zayas; G Izquierdo
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

3.  Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1).

Authors:  T Sahoo; E W Johnson; J W Thomas; P M Kuehl; T L Jones; C G Dokken; J W Touchman; C J Gallione; S Q Lee-Lin; B Kosofsky; J H Kurth; D N Louis; G Mettler; L Morrison; A Gil-Nagel; S S Rich; J M Zabramski; M S Boguski; E D Green; D A Marchuk
Journal:  Hum Mol Genet       Date:  1999-11       Impact factor: 6.150

4.  Computational and experimental analyses reveal previously undetected coding exons of the KRIT1 (CCM1) gene.

Authors:  T Sahoo; E Goenaga-Diaz; I G Serebriiskii; J W Thomas; E Kotova; J G Cuellar; J M Peloquin; E Golemis; F Beitinjaneh; E D Green; E W Johnson; D A Marchuk
Journal:  Genomics       Date:  2001-01-01       Impact factor: 5.736

5.  Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas.

Authors:  S Laberge-le Couteulx; H H Jung; P Labauge; J P Houtteville; C Lescoat; M Cecillon; E Marechal; A Joutel; J F Bach; E Tournier-Lasserve
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

6.  CCM1 gene mutations in families segregating cerebral cavernous malformations.

Authors:  W J Davenport; A M Siegel; J Dichgans; P Drigo; I Mammi; P Pereda; N W Wood; G A Rouleau
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

7.  KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation.

Authors:  I Eerola; K H Plate; R Spiegel; L M Boon; J B Mulliken; M Vikkula
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

8.  Cerebral cavernous malformation: novel mutation in a Chinese family and evidence for heterogeneity.

Authors:  Dong-Hui Chen; Hillary P Lipe; Zhen Qin; Thomas D Bird
Journal:  J Neurol Sci       Date:  2002-04-15       Impact factor: 3.181

9.  KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis.

Authors:  Jon S Zawistowski; Ilya G Serebriiskii; Maximilian F Lee; Erica A Golemis; Douglas A Marchuk
Journal:  Hum Mol Genet       Date:  2002-02-15       Impact factor: 6.150

10.  A novel KRIT1/CCM1 truncating mutation in a patient with cerebral and retinal cavernous angiomas.

Authors:  Sophie Laberge-Le Couteulx; Antoine P Brézin; Bertrand Fontaine; Elisabeth Tournier-Lasserve; Pierre Labauge
Journal:  Arch Ophthalmol       Date:  2002-02
View more
  83 in total

1.  Phosphorylation sites in the cerebral cavernous malformations complex.

Authors:  Jaehong Kim; Nicholas E Sherman; Jay W Fox; Mark H Ginsberg
Journal:  J Cell Sci       Date:  2011-12-01       Impact factor: 5.285

Review 2.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

3.  CCM1 gene deletion identified by MLPA in cerebral cavernous malformation.

Authors:  Sabine Gaetzner; Sonja Stahl; Oguzkan Sürücü; Anne Schaafhausen; Birgit Halliger-Keller; Helmut Bertalanffy; Ulrich Sure; Ute Felbor
Journal:  Neurosurg Rev       Date:  2006-12-23       Impact factor: 3.042

Review 4.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596

Review 5.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

6.  ccm2-like is required for cardiovascular development as a novel component of the Heg-CCM pathway.

Authors:  Jonathan N Rosen; Vanessa M Sogah; Lillian Y Ye; John D Mably
Journal:  Dev Biol       Date:  2013-01-15       Impact factor: 3.582

Review 7.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

8.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

9.  Cerebral Cavernous Malformations Develop Through Clonal Expansion of Mutant Endothelial Cells.

Authors:  Matthew R Detter; Daniel A Snellings; Douglas A Marchuk
Journal:  Circ Res       Date:  2018-10-26       Impact factor: 17.367

10.  Genetic Screening of Pediatric Cavernous Malformations.

Authors:  Elisa Merello; Marco Pavanello; Alessandro Consales; Samantha Mascelli; Alessandro Raso; Andrea Accogli; Armando Cama; Capra Valeria; Patrizia De Marco
Journal:  J Mol Neurosci       Date:  2016-08-25       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.